Nachrichten zur Incyte Corp. Aktie

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past…

…

Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor…

These are the stocks posting the largest moves in premarket trading.…

Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.…

Dublin, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The "Nebulizer Patent Landscape Report" report has been added to …

Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year…

Besides Wall Streets top -and-bottom-line estimates for Incyte (INCY), review projections for some of its key metrics to gain a…

INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe…

…

An der US-amerikanischen Börse notiert die Incyte-Aktie aktuell ein wenig leichter. Das Papier notiert zur Stunde bei 68,19 US-Dollar. Am…

The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally.…

…

INCYs phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer,…

Kulmbach (www.aktiencheck.de) - Incyte-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Incyte Corp. (ISIN: US45337C1027,…

Charlotte (www.aktiencheck.de) - Incyte-Aktienanalyse der Bank of America (BofA): Die Senkung des Kursziels für die Aktie von Incyte Corp. (ISIN: US45337C1027,…

After-hours movers: Super Micro Computer, Bakkt Holdings, Incyte, and more…

Though INCYs performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise…

Das Wertpapier von Incyte notiert am Montag etwas fester. Der jüngste Kurs betrug 66,16 US-Dollar. An der US-amerikanischen Börse hat…

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) hat heute neue klinische Daten über INCB123667 bekannt gegeben, einen hochgradig selektiven, potenziellen First-in-Class-CDK2 Inhibitor für…

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) gab heute positive Ergebnisse der zulassungsrelevanten Phase-3-Studie inMIND bekannt, in der die Wirksamkeit und Sicherheit…

…

On Incytes (INCY) second-quarter 2024 earnings call, investors focus is likely to be on the sales performance of its lead…

…

Incyte shares slip after BMO analysts cut rating of drugmaker…

An der US-amerikanischen Börse liegt der Anteilsschein von Incyte gegenwärtig im Plus. Zuletzt zahlten Investoren für das Wertpapier 64,06 US-Dollar.…

…

Stocks that are trading heavily or have substantial price changes on Monday: Incyte, Squarespace rise; Chimera Investment, Amazon fall…

Incyte shares dip after earnings, guidance miss…

Incyte earnings missed by $0.18, revenue fell short of estimates…

Incytes (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.…

Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.…

Incytes (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on…

HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”…

Incytes (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.…